A rare immune-related adverse event of pleural effusion after tislelizumab for non-small cell lung cancer: a case report and literature review Authors: Meibin Wang, Xinjian Dai, Zhihui Li Published: 2026 ABSTRACT BackgroundTislelizumab, a specific immune checkpoint inhibitor (ICI) targeting the programmed death protein-1 (PD-1) receptor, represents a novel immunotherapeutic approach for non-small cell lung cancer and has shown promising therapeutic potential. With the increasing clinical use of ICIs, immune-related adverse events (irAEs), including pneumonitis, thyroiditis, and pancreatitis, have been widely recognized. However, pleuritis presenting as pleural effusion (PE) in patients treated with tislelizumab has not yet been reported.Case presentationHere, we report the case of a 60-year-old man with primary lung squamous cell carcinoma who developed a new-onset PE. The patient had previously received treatment with tislelizumab, cisplatin, nab-paclitaxel, and radiotherapy. Notably, he had not received any systemic treatment during the six months preceding the onset of PE. Repeated thoracocenteses showed no malignant cells in the pleural fluid. Further evaluation, including medical thoracoscopy, showed no evidence of malignancy or radiation-induced pleuritis. Additionally, the PE was successfully controlled after corticosteroid therapy.ConclusionThis case suggests that late-onset PE may represent a rare form of irAE associated with ICIs and highlights the importance of continued monitoring for delayed irAEs during long-term tumor immunotherapy. Background The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of various malignancies and they have become a standard therapeutic strategy in oncology [1]. Tislelizumab, a monoclonal antibody that targets programmed cell death protein 1 (PD-1), has been approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (SCLC). Recent clinical trials have demonstrated that tislelizumab provides a significant overall survival (OS) benefit compared with conventional cytotoxic chemotherapy [2–5]. However, by enhancing T-cell activation, ICIs may trigger immune-related adverse events (irAEs). These adverse events encompass a broad and heterogeneous spectrum, affecting multiple systems and organs, including the lungs, endocrine glands, skin, liver, and gastrointestinal tract [6]. Lung parenchymal changes induced by pneumonitis are recognized as the most common pulmonary irAEs associated with ICIs. However, pleural injury associated with immunotherapy remains rare. Here, we report the first known case of pleuritis presenting as pleural effusion (PE) in a patient treated with tislelizumab. Case presentation A 60-year-old male patient was found to have a mass in the right lower lobe of his lung on a chest computed tomography (CT) scan during a routine physical examination in March 2023 (Fig. 1A). He underwent bronchoscopy at our hospital, and pathological examination confirmed lung squamous cell carcinoma (Fig. 1B, C). The patient received 4 cycles of neoadjuvant immunotherapy combined with chemotherapy, consisting of tislelizumab, nab-paclitaxel, and cisplatin. However, cisplatin was discontinued after the fourth cycle owing to myelosuppression. More than 3 months after completing neoadjuvant therapy, the patient underwent radical resection of the right lower lobe tumor in July 2023, followed by maintenance therapy with tislelizumab (Fig. 1D). After receiving 1 cycle of nab-paclitaxel and 4 cycles of tislelizumab maintenance therapy, the tislelizumab treatment was discontinued in October 2023 due to the development of checkpoint inhibitor-associated pneumonia (Fig. 1E). Unfortunately, stump recurrence was detected during a routine bronchoscopy in December 2023, and the patient was treated with concurrent chemoradiotherapy for 2 months (Fig. 1F). Follow-up chest CT scans demonstrated stable tumor status. Fig. 1The diagnostic workup on initial visit. A Chest CT scan showing a 6.1 x 5.0 cm mass in the posterior segment of the right lower lobe. B Bronchoscopic view showing obstruction of the right lower lobe bronchus. C H&E staining of Intratracheal neoplasm showing cytological features consistent with squamous cell carcinoma (100X). D The CT scan showing that the tumor had significantly shrunk after four cycles of neoadjuvant immunotherapy combined with chemotherapy. E CT scan showing right interstitial pneumonitis after 1 cycle of nab-paclitaxel and 4 cycles of tislelizumab maintenance therapy. F Bronchoscopic view showing the mucosal changes at the postoperative stump of the right lower lobe basal segment The diagnostic workup on initial visit. A Chest CT scan showing a 6.1 x 5.0 cm mass in the posterior segment of the right lower lobe. B Bronchoscopic view showing obstruction of the right lower lobe bronchus. C H&E staining of Intratracheal neoplasm showing cytological features consistent with squamous cell carcinoma (100X). D The CT scan showing that the tumor had significantly shrunk after four cycles of neoadjuvant immunotherapy combined with chemotherapy. E CT scan showing right interstitial pneumonitis after 1 cycle of nab-paclitaxel and 4 cycles of tislelizumab maintenance therapy. F Bronchoscopic view showing the mucosal changes at the postoperative stump of the right lower lobe basal segment However, in August 2024, 10 months after discontinuation of tislelizumab, the patient developed right-sided PE, as seen on a chest CT scan (Fig. 2A). Given the concern for tumor progression, the patient underwent thoracentesis (Table 1). The right pleural fluid was exudative and predominantly composed of lymphocytes (79%), with only 1% neutrophils. Acid-fast bacilli smear, bacterial culture, and tuberculosis DNA testing were all negative. Pleural fluid cytology from multiple thoracocenteses revealed no malignant cells. Moreover, carcinoembryonic antigen (CEA) levels were 1.5 µg/mL in both serum and PE. Serum autoimmune markers, including antinuclear antibodies, double-stranded DNA, anti-Sm antibodies, rheumatoid factor, antineutrophil cytoplasmic antibodies (ANCA), and immunoglobulin G4, were all within normal ranges. Despite the removal of 2000 mL of serous fluid by multiple pleural drainage procedures, the PE did not resolve. Given the persistent concern for pleural metastasis of lung cancer, he underwent right-sided medical thoracoscopy. Inspection of the parietal pleura revealed no abnormalities or signs of radiation-induced changes (Fig. 2B). Random parietal pleural biopsies showed non-specific chronic inflammatory changes, characterized by reactive mesothelial hyperplasia, focal cellulose-like material deposition, and a mixed inflammatory infiltrate composed of lymphocytes and neutrophils. No evidence of malignant cells or granulomatous lesions was identified (Fig. 2C). While these findings are not definitive for an immune-mediated etiology, they remain compatible with such a possibility in the appropriate clinical context. Chemotherapy-induced pleuritis typically occurs shortly after treatment, and radiation pleuritis was ruled out based on the normal appearance of the pleura. Given that immunotherapy can have long-lasting effects even after discontinuation, and in the absence of evidence of malignant progression, an irAE was suspected. In September 2024, the patient was started on a daily regimen of 40 mg methylprednisolone, which was gradually tapered. Ten days after initiating methylprednisolone, the patient’s PE resolved, and the tumor remained stable over the subsequent 15 months (Fig. 2D). The patient’s disease course is summarized in Fig. 3. Fig. 2Clinical course. A Chest CT scan showing the presence of PE. B Thoracoscopic view showing normal-appearing parietal pleura lining the anterior chest wall. C H&E stain of parietal pleural biopsy showing numerous reactive mesothelial hyperplasia with focal cellulose-like material consistent with chronic pleuritis(100X), without any granulomatous lesions or tumor cells. D Chest CT scan showing the pleural effusion significantly decreased after glucocorticoid treatment Clinical course. A Chest CT scan showing the presence of PE. B Thoracoscopic view showing normal-appearing parietal pleura lining the anterior chest wall. C H&E stain of parietal pleural biopsy showing numerous reactive mesothelial hyperplasia with focal cellulose-like material consistent with chronic pleuritis(100X), without any granulomatous lesions or tumor cells. D Chest CT scan showing the pleural effusion significantly decreased after glucocorticoid treatment Table 1Laboratory analysisVariablesResultUnitcoloryellowCells193110^6/LLym79%Neu1%Mono17%EOS*%Mesothelial cell3%RBC320010^6/LGlucose6.6mmol/LPretein40.6g/LADA4.8U/LLHD142U/LCEA1.5µg/LCulturenegativeCytologynegative Table 1Laboratory analysisVariablesResultUnitcoloryellowCells193110^6/LLym79%Neu1%Mono17%EOS*%Mesothelial cell3%RBC320010^6/LGlucose6.6mmol/LPretein40.6g/LADA4.8U/LLHD142U/LCEA1.5µg/LCulturenegativeCytologynegative Laboratory analysis Fig. 3Timeline for diagnosis, treatment and immune-related adverse events Timeline for diagnosis, treatment and immune-related adverse events Discussion ICIs combined with chemotherapy have become a standard first-line treatment option for NSCLC patients who lack actionable driver gene mutations, and this strategy has significantly improved patient survival outcomes [7]. However, ICI-based immunotherapy may also trigger irAEs, which can lead to immune-mediated injury affecting multiple organs and systems and have been reported to occur in up to 60% of treated patients [6]. ICI-induced organ dysfunction most commonly develops within 8–52 weeks after treatment initiation. Nevertheless, both earlier and delayed onset have been reported, ranging from as early as seven days to as late as 72 weeks, and in rare cases even up to 200 weeks after treatment [8]. Among patients with NSCLC receiving ICIs, immune checkpoint inhibitor-associated pneumonitis represents among the more common and potentially life-threatening pulmonary irAE. In contrast, PE and pleuritis related to ICIs are rarely reported [9]. The diagnosis of ICI-associated PE is challenging because it is largely a diagnosis of exclusion. Only a limited number of case reports have described PE occurring during treatment with ICIs, including camrelizumab, pembrolizumab, and nivolumab [7, 10, 11]. In the present case, PE developed 10 months after discontinuation of immunotherapy. Thoracentesis results revealed an exudative PE with a predominance of lymphocytes. Negative results for tuberculosis DNA and bacterial cultures suggested that infectious causes were unlikely. Repeated cytological examinations of pleural fluid and pleural biopsies showed no evidence of malignant cells, effectively ruling out the possibility of malignancy. Thoracoscopic evaluation showed a normal pleural appearance without signs of radiation-induced injury, making radiation pleuritis unlikely. In addition, serum autoimmune markers were negative, excluding autoimmune-related pleural disease. Chemotherapy-induced pleuritis generally occurs shortly after treatment; however, in this patient, the PE developed 6 months after discontinuation of anticancer therapy, making chemotherapy an unlikely cause. Other potential etiologies of PE, such as hypoalbuminemia, cardiac dysfunction, and collagen diseases, were also excluded. Taken together, the presence of persistent sterile lymphocytic effusion, repeated negative cytological examinations for malignancy, unremarkable thoracoscopic findings, and pleural biopsy demonstrating chronic inflammatory changes without evidence of tumor or radiation-induced injury, along with the rapid resolution of PE following glucocorticoid therapy, collectively support the possibility of immune-related pleuritis with PE. However, this remains a diagnosis of exclusion. In lung cancer patients who have received immunotherapy, the development of PE is often regarded as an indication of either disease progression or an irAE. In the present case, pleural dissemination or malignant PE were carefully excluded. Tislelizumab is a novel humanized IgG4 PD-1 inhibitor, independently developed in China. PD-1 is primarily expressed on T cells, whereas its ligands, programmed death-ligand 1 (PD-L1) and programmed death ligand-2 (PD-L2), are expressed on tumor cells, various normal tissues, and antigen-presenting cells. PD-1 is a negative regulator of T cell activity. The interaction between PD-1 and its ligands suppresses T-cell activation and helps maintain immune tolerance by promoting the differentiation of T helper type 1 (Th1) cells toward regulatory T cells (Tregs). Immunotherapy can activate T cells and promote their proliferation by inhibiting PD-1 or PD-L1, while simultaneously reducing the activity of Tregs, thereby inducing humoral autoimmune responses [12]. Moreover, overactivated T cells may mistakenly recognize normal pleural cells as targets, triggering an inflammatory response in the pleura. This process is also associated with the release of various cytokines and autoantibodies, including G-CSF, IFNa2, TNF-α, IL-1Ra, CXCL9 and CXCL10 [9, 13]. These cytokines may increase the permeability of the pleural capillaries, ultimately leading to the formation of PE. The ultra-long latency of approximately 10 months prior to the onset of PE in this case may be related to the sustained immunomodulatory effects of tislelizumab. ICIs are known to induce prolonged activation of T cells and remodeling of the immune microenvironment. Consequently, even after treatment discontinuation, dysregulated immune responses may persist and potentially contribute to tissue injury in specific organs, such as the pleura. Study limitations Several limitations of this study should be acknowledged. First, the occurrence of PE at an ultra-long latency—approximately 10 months after discontinuation of tislelizumab—limits the availability of direct temporal evidence supporting the association between pleural effusion and tislelizumab. The diagnosis of immune-related pleuritis is therefore based on a process of clinical exclusion and should be regarded as a presumptive interpretation rather than a definitive conclusion, given the absence of direct pathological or laboratory confirmation of the causal relationship. Second, as this is a single case report, the clinical characteristics and incidence of tislelizumab-associated PE remain uncertain and warrant further investigation in larger cohorts and well-designed retrospective studies. Conclusion In summary, tislelizumab combined with chemotherapy was effective in controlling NSCLC in this patient. To our knowledge, we report the first case of pleuritis with PE after tislelizumab therapy. Clinicians should be aware that PE may represent an irAE in patients receiving ICIs and should closely monitor for this possibility during prolonged immuno-oncology therapy. Notably, the present study is subject to limitations, particularly the ultra-long latency of the suspected irAE. Further accumulation of clinical cases is required to better clarify the potential relationship between tislelizumab and PE.